title: Are nelfinavir-containing regimens effective as second-line triple therapy?
authors.forename: E
authors.initials: E
authors.lastname: Bernasconi
authors.forename: L
authors.initials: L
authors.lastname: Magenta
authors.forename: J C
authors.initials: JC
authors.lastname: Piffaretti
authors.forename: A
authors.initials: A
authors.lastname: Carota
authors.forename: T
authors.initials: T
authors.lastname: Moccetti
mesh_terms: D015224:Dideoxynucleosides / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D019888:Nelfinavir / Q000627:therapeutic use*; D019829:Nevirapine / Q000627:therapeutic use; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D019888:Nelfinavir; D019829:Nevirapine; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000099227:Abacavir